Bannerbild German Brest Group

Congress contribution in 2019

SABCS: San Antonio Breast Cancer Simposium, December 10-14, 2019, San Antonio, Texas, USA

  • van Mackelenberg M, Seither F, Möbus V et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. SABCS 2019; GS1-07, oral presentation.
  • Williams T, Schneeweiss A, Jackisch C et al. Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer. SABCS 2019; P1-10-01, poster.
  • Blohmer J, Link T, Kümmel S et al. Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study. SABCS 2019; GS3-01, oral presentation.
  • Fasching PA, Denkert C, Benz S et al. Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - an analysis of the GeparSepto trial. SABCS 2019; PD5-08, poster discussion.
  • Fröhlich K, Plösch T, Seither F et al. Histological and epigenetic analyses of placenta tissue from breast cancer patients and healthy participants. SABCS 2019; P4-04-08, poster.
  • Loibl S, Untch M, Buyse M et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC). SABCS 2019; P5-06-02, poster.
  • Szeto C, Denkert C, Fasching PA et al. Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations. SABCS 2019;P6-10-04, poster.
  • Furlanetto J, Möbus V, Schneeweiss A et al. Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT). SABCS 2019;P6-10-03, poster.
  • Piccart M, Procter M, Fumagalli D et al. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019;GS1-04, oral presentation.
  • Cuzick J, Sestak I, Forbes J et al. (IBIS-II investigators). Ten year results of the international breast cancer intervention study II. SABCS 2019;GS4-04, oral presentation.
  • Mano MS, Loibl S, Mamounas EP et al. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. SABCS 2019;P3-14-01, poster.
  • Geyer CE Jr, Loibl S, Rastogi P et al. A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze. SABCS 2019;OT2-04-08, poster.
  • Jerusalem G, Farah S, Chirgwin J et al. Sole (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (bc): final analysis and sole estrogen substudy (sole-est). SABCS 2019; P5-12-01, poster.

DGP: 103. Jahrestagung der Deutschen Gesellschaft für Pathologie, June 13-15 2019, Frankfurt am Main, Germany

  • Sinn BV, Loibl S, Karn T et al. Expression von PD-L1 und dynamische Veränderungen tumor-infiltrierender Lymphozyten bei neoadjuvanter Chemotherapie mit Immun-Checkpunkt-Blockade beim frühen triple-negativen Mammakarzinom. DGP 2019, AG05.02, oral presentation.

ESMO: European Society for Medical Oncology, September 27-October 1, 2019 Barcelona, Spain

  • Furlanetto J, Nekljudova V, Schneeweiss A et al. Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC). Ann Oncol 2019;Volume 30, Issue Suppl_5, 180PD, poster discussion.
  • Marmé F, Solbach C, Michel L et al. Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ann Oncol 2019;Volume 30, Issue Suppl_5, 182PD, poster discussion.
  • Werutsky G, Untch M, Hanusch C et al. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials. Ann Oncol 2019;Volume 30, Issue Suppl_5, 188P, poster.
  • Tesch H, Loibl S, Kast K et al. Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study. Ann Oncol 2019;Volume 30, Issue Suppl_5, 195P, poster.
  • Untch M, Geyer C, Huang C et al. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Ann Oncol 2019;Volume 30, Issue Suppl_5, LBA19, oral presentation.

DGS: Deutsche Gesellschaft für Senologie 39. Jahrestagung, June 27-29, 2019 Berlin, Germany

  • Banys-Paluchowski M, Loibl S, Witzel I et al. Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the GeparQuinto trial. DGS 2019, #094, poster.
  • Reimer T. Update NSEMA-Studie. DGS 2019; oral presentation.

ASCO: American Society of Clinical Oncology, Annual Meeting May 31-4 June, 2019, Chicago, IL, USA

  • Denkert C, Link T, Jank P et al. Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial. J Clin Oncol 2019;37.15_suppl.3075, poster.
  • Loibl S, Sinn BV, Karn T et al. Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial. J Clin Oncol 2019;37.15_suppl.509, poster discussion.
  • Seliger B, Karn T, Denkert C et al. Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. J Clin Oncol 2019;37.15_suppl.588, poster.
  • Pohl-Rescigno E, Hauke J, Rhiem K et al. Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344). J Clin Oncol 2019;37.15_suppl.573, poster.
  • Fasching PA, Jackisch C, Rhiem K et al. GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J Clin Oncol 2019;37.15_suppl.506, oral presentation.
  • Geyer CE, Loibl S, Rastogi P et al. NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. J Clin Oncol 2019;37.15_suppl.TPS605, poster.
  • Krop IE, Paulson J, Campbell C et al. Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. J Clin Oncol 2019;37.15_suppl.1012, oral presentation.
  • Schneeweiss A, Loib S, Mamounas EP et al. Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. J Clin Oncol 2019;37.15_suppl.513, poster discussion.
  • Metzger O, Stover DG, Asad S et al. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. J Clin Oncol 2019; 37.15_suppl.510, poster discussion.

ESMO-Breast Cancer 2019, May 2-4, 2019 Berlin, Germany

  • Huober J, Schneeweiss A, Blohmer JU et al. Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database. Ann Oncol 2019; 30 (suppl_3): iii34-iii38; #1080, oral presentation.
  • Jank P, Loibl S, Fasching PA et al. Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials. Ann Oncol 2019; 30 (suppl_3): iii1-iii26, #15P, poster.
  • Loibl S, Jackisch C, Rastogi P et al. GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. Ann Oncol 2019; 30 (suppl_3): iii34-iii38, #122TiP, poster.
  • Denkert C, Link T, Jank P et al. (on behalf of the GBG neoadjuvant and translational subboard). Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment. Ann Oncol 2019; 30 (suppl_3): iii1-iii26, #25P, poster.
  • Karn T, Denkert C, Weber KE. et al. Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling. Ann Oncol 2019; 30 (suppl_3): iii1-iii26, #9O, poster discussion.

News

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd